{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=80", "query": { "intervention": "Placebo", "page": 80 }, "page_size": 10 }, "pagination": { "page": 80, "page_size": 10, "total_count": 33180, "total_pages": 3318, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=81&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=79&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-12T17:20:51.514Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00723385", "title": "Effects of Vitamin D on Lipids", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hypercholesterolemia", "Vitamin D Deficiency" ], "interventions": [ { "name": "Vitamin D (1000 or 2000 IU/day)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2008-07", "completion_date": "2012-07", "has_results": false, "last_update_posted_date": "2015-04-08", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00723385" }, { "nct_id": "NCT00186043", "title": "Seroquel in the Treatment of Dysphoric Hypomania in Bipolar II", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bipolar II Disorder" ], "interventions": [ { "name": "Quetiapine/Seroquel", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 55, "start_date": "2008-08", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2017-09-27", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00186043" }, { "nct_id": "NCT03538015", "title": "Carvedilol in Treating Hypoglycemia Unawareness", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hypoglycemia Unawareness" ], "interventions": [ { "name": "Carvedilol 3.125 mg", "type": "DRUG" }, { "name": "Carvedilol 2.5 mg", "type": "DRUG" }, { "name": "Placebo capsule", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Owen Chan, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2019-04-22", "completion_date": "2020-08-10", "has_results": true, "last_update_posted_date": "2020-11-25", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT03538015" }, { "nct_id": "NCT00987415", "title": "Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Heart Failure", "Elevated Serum Uric Acid" ], "interventions": [ { "name": "allopurinol", "type": "DRUG" }, { "name": "sugar pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2010-05", "completion_date": "2014-06", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 9, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 6 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00987415" }, { "nct_id": "NCT04311515", "title": "To Evaluate Safety, Tolerability and Pharmacological Effects of PU AD in Subjects With Mild AD Dementia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease" ], "interventions": [ { "name": "Tau Positron emission tomography (PET)", "type": "RADIATION" }, { "name": "Fluorodeoxyglucose (FDG) Positron emission tomography (PET)", "type": "RADIATION" }, { "name": "Cerebrospinal fluid (CSF) Biomarkers", "type": "DIAGNOSTIC_TEST" }, { "name": "Blood Biomarkers", "type": "DIAGNOSTIC_TEST" }, { "name": "Rating Scales", "type": "BEHAVIORAL" }, { "name": "PU-AD", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DIAGNOSTIC_TEST", "BEHAVIORAL", "DRUG" ], "sponsor": "Samus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "55 Years to 80 Years" }, "enrollment_count": 4, "start_date": "2020-06-30", "completion_date": "2022-11-15", "has_results": false, "last_update_posted_date": "2022-11-17", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 10, "location_summary": "Boca Raton, Florida • Delray Beach, Florida • Lake Worth, Florida + 6 more", "locations": [ { "city": "Boca Raton", "state": "Florida" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "Lake Worth", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04311515" }, { "nct_id": "NCT03663335", "title": "Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Kidney Transplantation" ], "interventions": [ { "name": "CFZ533 - Cohort 1/Cohort 2", "type": "BIOLOGICAL" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" }, { "name": "Corticosteroids (CS)", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Induction therapy: basiliximab", "type": "DRUG" }, { "name": "Induction therapy: rabbit anti-thymocyte globulin (rATG)", "type": "DRUG" }, { "name": "Maintenance population: EC-MPS", "type": "DRUG" }, { "name": "Maintenance population: MMF", "type": "DRUG" }, { "name": "Placebo 1 mL", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 418, "start_date": "2018-11-28", "completion_date": "2021-10-29", "has_results": true, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03663335" }, { "nct_id": "NCT01738308", "title": "The Effects of Healing Touch on Post Operative Pediatric Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Surgery", "Stress", "Pain", "Children", "Post-Traumatic Stress Disorder" ], "interventions": [ { "name": "Healing Touch", "type": "PROCEDURE" }, { "name": "Healing Touch Sham Treatment", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "3 Years", "maximum_age": "4 Years", "sex": "ALL", "summary": "3 Years to 4 Years" }, "enrollment_count": 240, "start_date": "2013-09", "completion_date": "2017-06", "has_results": false, "last_update_posted_date": "2021-06-24", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01738308" }, { "nct_id": "NCT05416125", "title": "Vyvanse in Children Aged 6 to 12 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Obesity, Childhood" ], "interventions": [ { "name": "Lisdexamfetamine Dimesylate", "type": "DRUG" }, { "name": "Lifestyle therapy", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Years", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Years to 12 Years" }, "enrollment_count": 44, "start_date": "2023-12-20", "completion_date": "2026-06-23", "has_results": false, "last_update_posted_date": "2026-08-10", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05416125" }, { "nct_id": "NCT02583789", "title": "Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Raynaud's Phenomenon" ], "interventions": [ { "name": "oral treprostinil", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 12, "start_date": "2016-05", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2022-01-10", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02583789" }, { "nct_id": "NCT00225589", "title": "A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesteremia" ], "interventions": [ { "name": "Rosuvastatin calcium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "45 Years to 70 Years" }, "enrollment_count": 840, "start_date": "2002-08", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2010-11-19", "last_synced_at": "2026-11-12T17:20:51.514Z", "location_count": 20, "location_summary": "Alhambra, California • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Alhambra", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Santa Ana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00225589" } ] }